Deal Memo · Allied Venture Partners
Why the firm invested
Allied Venture Partners believes ROOK has strong potential to generate venture-scale returns if it achieves its 3-to-5-year projected milestones.
Therefore, if we are correct in our thesis and the company achieves its projected milestones over the next 3-5 years, we believe Rook has strong potential to generate a significant venture-scale return for stakeholders.
Product
ROOK enables health, wellness, and fitness applications to access and use real-time data from any wearable device via API.
ROOK enables health, wellness, and fitness applications to access and use data from any wearable device in real-time via API.
Traction
After completing Techstars in Q2 2022, ROOK launched its commercial product in August 2022 and rapidly grew enterprise contract revenue.
After completing Techstars in Q2’22, they launched their commercial product in August and have since grown to over [redacted for privacy] in enterprise contracts.
Team
ROOK's technical team includes biomedical and software engineers who have previously led clinical research teams at pharma giants Novartis and Roche.
Headquartered in Miami, the team has deep technical and industry expertise, comprised of biomedical and software engineers with years of experience designing software integrations for medical devices, and health applications, and have led clinical research teams at pharma giants Novartis and Roche.
Business model
ROOK provides a Health-data-as-a-Service solution via API that is charged on a per active user basis.
Similar to what Plaid has done to standardize financial data, Rook’s “Health-data-as-a-Service” (HaaS) solution is provided by API and charged per active user.
Competition
ROOK holds a proprietary advantage as the only solution currently capable of real-time health data standardization.
With Rook’s proprietary advantage as the only solution currently capable of providing real-time data standardization, we believe Rook has the potential to become the dominant player in a market with minimal competition.
What founders can learn
- What actually moved the decision: Allied Venture Partners wrote that Allied Venture Partners believes ROOK has strong potential to generate venture-scale returns if it achieves its 3-to-5-year projected milestones.
- The traction evidence that carried weight: Allied Venture Partners wrote that After completing Techstars in Q2 2022, ROOK launched its commercial product in August 2022 and rapidly grew enterprise contract revenue.
- How the team was judged: Allied Venture Partners wrote that ROOK's technical team includes biomedical and software engineers who have previously led clinical research teams at pharma giants Novartis and Roche.
- How the model was assessed: Allied Venture Partners wrote that ROOK provides a Health-data-as-a-Service solution via API that is charged on a per active user basis.
Source and provenance
Deal Memo published by Allied Venture Partners on allied.vc (first-party source). Read the original
